Recombinant aav virion for expressing epo in a mammal
CA 2243470 C · Owner: Avigen, Inc. · Inventors: Podsakoff, Gregory M.; Kurtzman, Gary J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct in vivo injection of , recombinant AAV virions into muscle tissue e.g. by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 17, 1997 and granted October 28, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 17, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 17, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.